Please assess the completion status of the following clinical trial:

Trial Title: Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Received an autologous or allogeneic hematopoietic stem cell transplant (HSCT) using any conditioning regimen~* Absolute lymphocyte count (ALC) less than (\<) 1,000 cells/microliter (mL)~* Participant has laboratory confirmed RSV diagnosis within 48 hours of randomization~* New onset of at least 1 of the following respiratory symptoms within 4 days prior to the anticipated start of dosing nasal congestion, rhinorrhea, cough or pharyngitis (sore throat), and/or worsening of one of these chronic (associated with previously existing diagnosis, example, chronic rhinorrhea, seasonal allergies, chronic lung disease) respiratory symptoms within 4 days prior to the anticipated start of dosing~* Peripheral capillary oxygen saturation (SpO2) greater than or equal to (\>=) 92 percent (%) on room air~Exclusion Criteria:~* Admitted to the hospital primarily for a lower respiratory tract disease of any cause as determined by the investigator~* Requires supplemental oxygen at Screening or any time between Screening and randomization~* Documented to be positive for other respiratory viruses (limited to influenza, parainfluenza, human rhinovirus, adenovirus, human metapneumovirus, or coronavirus) within 7 days prior to or at the Screening visit, if determined by local SOC testing (additional testing is not required)~* Clinically significant bacteremia or fungemia within 7 days prior to or at Screening that has not been adequately treated, as determined by the investigator

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Adult cohort: JNJ-53718678 or Placebo (Type: EXPERIMENTAL): Participants greater than or equal to (\>=) 18 to less than or equal to (\<=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
- Adolescent cohort: JNJ-53718678 or Placebo (Type: EXPERIMENTAL): Participants \>=13 to \<18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).